Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
Do investment tax breaks work? A new study finds the evidence is ‘mixed at best’ 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout 
South Korea to End Short-Selling Ban as Financial Market Uncertainty Persists 
Why your retirement fund might soon include cryptocurrency 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO 
KiwiSaver shakeup: private asset investment has risks that could outweigh the rewards 
U.S. Stock Futures Rise as Trump Takes Office, Corporate Earnings Awaited 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
Tesla Faces 19% Drop in UK Registrations as Competition Intensifies 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
U.S. Banks Report Strong Q4 Profits Amid Investment Banking Surge 
Trump Administration to Secure Equity Stake in Pat Gelsinger’s XLight Startup 
Samsung Biologics would invest 1.74 trillion in building a massive fourth plant in Songdo, Incheon, that would employ 1,800 new employees by 2023 and produce 256,000 liters of drug substances in a single generation.
According to CEO Kim Tae-han, the construction will increase its output at its Songdo complex 1 to 620,000 liters, accounting for 30 percent of the world’s contract manufacturing market.
Samsung Biologics currently has a combined 364,000-liter capacity at its three existing plants, with one of those producing 180,000 liters and touted as having the world’s largest single-plant capacity.
Construction of the fourth plant will take 36 months and poised to create 27,000 jobs and bring in 5.6 trillion won in economic benefits.
Plant 4 will be a hybrid that has both stainless steel and single-use disposable bioreactors.
With speed being of critical significance in the biologics market, the new plant will be a game-changer.
It would provide a one-stop service comprising of cell line development and the manufacturing of clinical samples, active pharmaceutical ingredients, drug substances, and fill-and-finish drug products.
The one-stop service would dramatically reduce the time spent on commercializing a drug.
